Ronaldo Soares Maia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ronaldo Soares Maia has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Amauri Moreira Leite Junior
Universidade Nove de Julho
1 shared publication - Beatriz Brandão da Silva Navas
Universidade Nove de Julho
1 shared publication - Beatriz Sanches Molina
Universidade Nove de Julho
1 shared publication - Beatriz Taveira Constantinou
Universidade Nove de Julho
1 shared publication - Bianca Caroline Benedicto
Universidade Nove de Julho, São Bernardo do Campo São Paulo Brazil
1 shared publication - Fernando Gonçalves Almeida
Universidade Federal de Sao Paulo, Brasil
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Acta Cirurgica Brasileira
- Vol. 41
Use of pumpkin seed (Cucurbita pepo) versus placebo and versus alpha-blockers in the management of benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials
Purpose: To compare pumpkin seed (Cucurbita pepo) with placebo and, separately, with alpha-blockers in men with benign prostatic hyperplasia-related lower urinary tract symptoms. Methods: Five databases were searched to 30 April 2025 for randomized controlled trials (RCTs). The primary outcome was change in international prostate symptom score (IPSS), and secondary outcomes included maximum urinary flow (Qmax), prostate volume, prostate-specific antigen (PSA) and adverse events. Each comparator was analyzed separately by random-effects meta-analysis, with RoB 2 for risk of bias. Results: Eight RCTs (2,170 men) were included. Versus placebo, pumpkin seed reduced IPSS at three months (mean difference -0.62, 95% confidence interval [95%CI] -1.15 to -0.09) but not at six months; versus alpha-blockers there was no difference (1.91, IC95% -0.24–4.07). Qmax improved versus placebo only; no other outcome differed from alpha-blockers. Adverse events were fewer with pumpkin seed in one head-to-head trial (odds ratio = 0.21, IC95% 0.07–0.63). Conclusion: Pumpkin seed offers at most a small sub-clinical IPSS benefit over placebo, not maintained at six months, and no significant difference from alpha-blockers. Certainty was low to very low; equivalence is not established.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Acta Cirurgica Brasileira
- Vol. 41
Open AccessUse of pumpkin seed (Cucurbita pepo) versus placebo and versus alpha-blockers in the management of benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials
Purpose: To compare pumpkin seed (Cucurbita pepo) with placebo and, separately, with alpha-blockers in men with benign prostatic hyperplasia-related lower urinary tract symptoms. Methods: Five databases were searched to 30 April 2025 for randomized controlled trials (RCTs). The primary outcome was change in international prostate symptom score (IPSS), and secondary outcomes included maximum urinary flow (Qmax), prostate volume, prostate-specific antigen (PSA) and adverse events. Each comparator was analyzed separately by random-effects meta-analysis, with RoB 2 for risk of bias. Results: Eight RCTs (2,170 men) were included. Versus placebo, pumpkin seed reduced IPSS at three months (mean difference -0.62, 95% confidence interval [95%CI] -1.15 to -0.09) but not at six months; versus alpha-blockers there was no difference (1.91, IC95% -0.24–4.07). Qmax improved versus placebo only; no other outcome differed from alpha-blockers. Adverse events were fewer with pumpkin seed in one head-to-head trial (odds ratio = 0.21, IC95% 0.07–0.63). Conclusion: Pumpkin seed offers at most a small sub-clinical IPSS benefit over placebo, not maintained at six months, and no significant difference from alpha-blockers. Certainty was low to very low; equivalence is not established.